Functional disorders of polymorphonuclear neutrophils (D71) ICD-10-CM
The D71 code range covers functional disorders of polymorphonuclear neutrophils with 4 ICD-10-CM diagnosis codes. 3 of them are billable and valid for claim submission in fiscal year 2026, and the category headers group them but cannot themselves be billed.
Codes in the D71 Range 4 codes · 3 billable
About the D71 Code Range
The ICD-10 code D71 is used to identify functional disorders of polymorphonuclear neutrophils, which are specialized white blood cells important for fighting infections. These disorders affect the neutrophils’ ability to perform their normal immune functions, leading to repeated infections and other complications.
Specifically, this code covers conditions such as chronic granulomatous disease in its various types (I, IA, IIA, II, III, IVA, IV), a group of inherited disorders where neutrophils cannot effectively kill certain bacteria and fungi. It also includes related terms like neutrophil lactoferrin deficiency and complications stemming from granulomatous disease, such as hypopituitarism, hypoparathyroidism, hypercalcemia, and interstitial lung disease. These synonyms help clarify that when coding for these complex immune dysfunctions, D71 captures a range of granulomatous and neutrophil functional disorders. Medical coders can rely on this code when documenting these specific immune abnormalities for accurate clinical and billing records.
Questions About This Page
How many billable codes are in the D71 range?
Of the 4 codes in this range, 3 are billable and valid for claim submission from October 1, 2025 through September 30, 2026. Category header codes group them but cannot be reported on claims.
What does the D71 range classify?
The range classifies functional disorders of polymorphonuclear neutrophils. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.
Related References
Source: CMS FY 2026 ICD-10-CM Tabular List and order file, effective October 1, 2025 through September 30, 2026.
